volume 34 issue 2 pages 101-116

CRISPR as a driving force: the Model T of biotechnology

Publication typeJournal Article
Publication date2016-06-01
scimago Q1
wos Q2
SJR0.381
CiteScore2.3
Impact factor1.6
ISSN13212753, 18366716
General Medicine
Abstract
The CRISPR system for gene editing can break, repair, and replace targeted sections of DNA. Although CRISPR gene editing has important therapeutic potential, it raises several ethical concerns. Some bioethicists worry CRISPR is a prelude to a dystopian future, while others maintain it should not be feared because it is analogous to past biotechnologies. In the scientific literature, CRISPR is often discussed as a revolutionary technology. In this paper we unpack the framing of CRISPR as a revolutionary technology and contrast it with framing it as a value-threatening biotechnology or business-as-usual. By drawing on a comparison between CRISPR and the Ford Model T, we argue CRISPR is revolutionary as a product, process, and as a force for social change. This characterization of CRISPR offers important conceptual clarity to the existing debates surrounding CRISPR. In particular, conceptualizing CRISPR as a revolutionary technology structures regulatory goals with respect to this new technology. Revolutionary technologies have characteristic patterns of implementation, entrenchment, and social impact. As such, early identification of technologies as revolutionary may help construct more nuanced and effective ethical frameworks for public policy.
Found 
Found 

Top-30

Journals

1
Journal of Agricultural and Environmental Ethics
1 publication, 16.67%
Molecular Therapy - Methods and Clinical Development
1 publication, 16.67%
Human Reproduction
1 publication, 16.67%
Topics in Biodiversity and Conservation
1 publication, 16.67%
Journal of Ethics
1 publication, 16.67%
1

Publishers

1
2
3
Springer Nature
3 publications, 50%
Elsevier
2 publications, 33.33%
Oxford University Press
1 publication, 16.67%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Share
Cite this
GOST |
Cite this
GOST Copy
Mariscal C., Petropanagos A. CRISPR as a driving force: the Model T of biotechnology // Monash bioethics review. 2016. Vol. 34. No. 2. pp. 101-116.
GOST all authors (up to 50) Copy
Mariscal C., Petropanagos A. CRISPR as a driving force: the Model T of biotechnology // Monash bioethics review. 2016. Vol. 34. No. 2. pp. 101-116.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1007/s40592-016-0062-2
UR - https://doi.org/10.1007/s40592-016-0062-2
TI - CRISPR as a driving force: the Model T of biotechnology
T2 - Monash bioethics review
AU - Mariscal, Carlos
AU - Petropanagos, Angel
PY - 2016
DA - 2016/06/01
PB - Springer Nature
SP - 101-116
IS - 2
VL - 34
PMID - 27619650
SN - 1321-2753
SN - 1836-6716
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2016_Mariscal,
author = {Carlos Mariscal and Angel Petropanagos},
title = {CRISPR as a driving force: the Model T of biotechnology},
journal = {Monash bioethics review},
year = {2016},
volume = {34},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1007/s40592-016-0062-2},
number = {2},
pages = {101--116},
doi = {10.1007/s40592-016-0062-2}
}
MLA
Cite this
MLA Copy
Mariscal, Carlos, and Angel Petropanagos. “CRISPR as a driving force: the Model T of biotechnology.” Monash bioethics review, vol. 34, no. 2, Jun. 2016, pp. 101-116. https://doi.org/10.1007/s40592-016-0062-2.